Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype

Human endogenous retroviruses (HERVs), which make up approximately 8% of the human genome, are overexpressed in some breast cancer cells and tissues but without regard to cancer subtype. We, therefore, analyzed TCGA RNA-Seq data to evaluate differences in expression of the HERV-K family in breast cancers of the various subtypes. Four HERV-K loci on different chromosomes were analyzed in basal, Her2E, LumA, and LumB breast cancer subtypes of 512 breast cancer patients with invasive ductal carcinoma (IDC). The results for all four loci showed higher HERV-K expression in the basal subtype, suggesting similar mechanisms of regulation regardless of locus. Expression of the HERV-K envelope gene (env) was highly significantly increased in basal tumors in comparison with the also-upregulated expression of other HERV-K genes. Analysis of reverse-phase protein array data indicated that increased expression of HERV-K is associated with decreased mutation of H-Ras (wild-type). Our results show elevation of HERV-K expression exclusively in the basal subtype of IDC breast cancer (as opposed to the other subtypes) and suggest HERV-K as a possible target for cancer vaccines or immunotherapy against this highly aggressive form of breast cancer.

[1]  C. Hao,et al.  PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis , 2014, Oncology letters.

[2]  Carmen Jerónimo,et al.  P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation , 2005, Clinical Cancer Research.

[3]  E. Meese,et al.  Human Endogenous Retrovirus Family HERV-K(HML-5): Status, Evolution, and Reconstruction of an Ancient Betaretrovirus in the Human Genome , 2004, Journal of Virology.

[4]  F. McCormick,et al.  Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. , 2013, Cancer discovery.

[5]  J. Ruppert,et al.  MicroRNA‐Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer , 2015, Drug development research.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[7]  J. Reis-Filho,et al.  Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer , 2007, Modern Pathology.

[8]  K. Hunt,et al.  Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras , 2015, Oncoimmunology.

[9]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[10]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Zvelebil,et al.  Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers , 2013, Breast Cancer Research.

[12]  Selvaraju Veeriah,et al.  Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition , 2013, Breast Cancer Research.

[13]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[14]  A. Skoultchi,et al.  CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells , 2003, Oncogene.

[15]  D. Edwards,et al.  Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. , 2015, Cell reports.

[16]  J. Weinstein,et al.  Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes , 2014, Oncotarget.

[17]  S. Olivares,et al.  Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma , 2015, Clinical Cancer Research.

[18]  K. Hess,et al.  Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early‐stage breast cancer , 2014, International journal of cancer.

[19]  Francis Harper,et al.  Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements. , 2006, Genome research.

[20]  L. Ramondetta,et al.  Cytotoxicity of Human Endogenous Retrovirus K–Specific T Cells toward Autologous Ovarian Cancer Cells , 2014, Clinical Cancer Research.

[21]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[22]  K. Hunt,et al.  Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. , 2012, Journal of the National Cancer Institute.

[23]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[24]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[25]  J. Lenz,et al.  A Single Amino Acid Substitution in a Segment of the CA Protein within Gag That Has Similarity to Human Immunodeficiency Virus Type 1 Blocks Infectivity of a Human Endogenous Retrovirus K Provirus in the Human Genome , 2008, Journal of Virology.

[26]  S. Byers,et al.  Soluble‐E‐cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers , 2014, Molecular carcinogenesis.

[27]  R. Blamey,et al.  E-cadherin as a prognostic indicator in primary breast cancer , 2001, British Journal of Cancer.

[28]  G. Bourque,et al.  The Majority of Primate-Specific Regulatory Sequences Are Derived from Transposable Elements , 2013, PLoS genetics.

[29]  K. Khalili,et al.  Evidence that a cell cycle regulator, E2F1, down-regulates transcriptional activity of the human immunodeficiency virus type 1 promoter , 1995, Journal of virology.

[30]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[31]  A. Ribeiro,et al.  P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an “Intermediate/Metastable” EMT State , 2014, Front. Oncol..

[32]  F. Pedersen,et al.  Human endogenous retroviruses sustain complex and cooperative regulation of gene-containing loci and unannotated megabase-sized regions , 2015, Retrovirology.

[33]  R. Weiss,et al.  Human endogenous retroviruses: friend or foe? , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[34]  T. Heidmann,et al.  Identification of a Functional Envelope Protein from the HERV-K Family of Human Endogenous Retroviruses , 2005, Journal of Virology.

[35]  Charles M Perou,et al.  EGFR associated expression profiles vary with breast tumor subtype , 2007, BMC Genomics.

[36]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[37]  J. Coffin,et al.  Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses , 2011, Retrovirology.

[38]  J. Montero,et al.  Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer , 2014, Oncogene.

[39]  B. Law,et al.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. , 2008, Neoplasia.

[40]  J. Kidd,et al.  Discovery of unfixed endogenous retrovirus insertions in diverse human populations , 2016, Proceedings of the National Academy of Sciences.

[41]  J. Lees,et al.  Life and death decisions by the E2F transcription factors. , 2007, Current opinion in cell biology.

[42]  Minetta C. Liu,et al.  Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers , 2014, Clinical Cancer Research.

[43]  Gabor T. Marth,et al.  MOSAIK: A Hash-Based Algorithm for Accurate Next-Generation Sequencing Short-Read Mapping , 2013, PloS one.

[44]  Yongchang Wei,et al.  Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells , 2016, Oncotarget.

[45]  Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. , 2010, The American journal of pathology.

[46]  Xianxiao Zhou,et al.  An Integrated Approach to Uncover Driver Genes in Breast Cancer Methylation Genomes , 2013, PloS one.

[47]  X. Xu,et al.  The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells , 2013, Leukemia.

[48]  K. Hunt,et al.  Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. , 2008, Cancer research.

[49]  K. Kidd,et al.  Insertional polymorphisms of full-length endogenous retroviruses in humans , 2001, Current Biology.